Long-term effects of finasteride on prostate tissue composition
| Autor: | Elizabeth Stoner, Maria Luz Macairan, Jonathan I. Epstein, Frederick J. Dorey, Paul Bryan C. Santos, Joel B. Garris, Leonard S. Marks, Glenn J. Gormley, Alan W. Partin, Erlinda D. Shery, Jean B. deKernion |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Prostate biopsy biology Adenoma medicine.diagnostic_test business.industry Urology Hyperplasia medicine.disease biology.organism_classification Epithelium chemistry.chemical_compound Endocrinology medicine.anatomical_structure chemistry Prostate Internal medicine Dihydrotestosterone medicine Serenoa Finasteride business medicine.drug |
| Zdroj: | Urology. 53:574-580 |
| ISSN: | 0090-4295 |
| Popis: | Objectives. To determine the long-term effects of finasteride treatment on prostate tissue composition; to relate these effects to clinical outcomes; and to test the hypothesis that finasteride exerts a selective or preferential action on the transition zone. Methods. Nineteen men with symptomatic benign prostatic hyperplasia (BPH) who completed a 6-month double-blind trial of finasteride were enrolled in a 24-month open-label extension study of drug responders. Magnetic resonance imaging and prostate biopsy for morphometric analysis were performed together 70 times: at baseline (n = 19), after treatment periods of intermediate duration (6 to 18 months, n = 32), and after long-term drug treatment (24 to 30 months, n = 19). At baseline, prostate volume averaged 51 cc, of which 57% was transition zone. Results. Decreases in symptom score, dihydrotestosterone and prostate-specific antigen levels, and prostate volume occurred at 6 months (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect